While our findings demonstrate that FBL promotes tumor aggressiveness and resistance to chemotherapy, they do not explore whether FBL expression varies across key molecular CRC subtypes such as MSI-H, MSS, or RAS/BRAF-mutant tumors. This evidence concerns the gene FBL and colorectal carcinoma.